Another analyzed molecular target, the inhibition of which could improve the results of AML therapy, consists of mutations in the genes encoding isocitrate dehydrogenase isoform 1 (IDH1) and isocitrate dehydrogenase isoform 2 (IDH2), occurring at a frequency of 8–17% and 12–19% of AML cases, respectively [10,11,12,13,14]. Here, IDH2 is linked to acute myeloid leukemia.